Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry

This article was originally published in The Tan Sheet

Executive Summary

FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say
Advertisement

Related Content

Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Comment on FDAAA provision
FDA Stymied By Reauthorization Terms That May Slow Ingredient Development

Topics

Advertisement
UsernamePublicRestriction

Register

PS102375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel